Department of Cardiovascular Surgery, Faculty of Medicine, Fırat University, Elazığ, Turkey.
Turk J Med Sci. 2021 Oct;51(5):2763-2770. doi: 10.3906/sag-2104-68. Epub 2021 Oct 21.
In this study, we aimed to investigate the effects of antioxidant iloprost (ILO) and ß3 adrenergic receptor agonist (BRL) on transient receptor potential ankyrin 1 (TRPA1) and transient receptor potential canonical 1 (TRPC1) ion channels on an experimental ischemia and reperfusion injury model in 30 male Wistar albino rats aged 8-10 weeks.
Wistar Albino rats aged were divided into 5 equal groups. Group I Sham operation, Group II IR (ischemiareperfusion) procedure, Group III IR + intravenous ILO administration, Group IV IR + intraperitoneal BRL administration, and Group V IR + intravenous ILO + intraperitoneal BRL administration group. Two ng/kg/min ILO intravenous infusion was applied to the ILO group. A single dose of 5 mcg/kg BRL intraperitoneal was applied to BRL group. TOS (total oxidant status), TRPA1, and TRPC1 levels were measured with ELISA (enzyme linked immunosorbent assay) in serum, immunohistochemical staining in musculus quadriceps femoris tissue.
Compared with the sham group, the IR group had a statistically significant increase in serum levels of TOS (p = 0.004), TRPA1 (p = 0.002), and TRPC1 (p = 0.008) along with TRPA1- and TRPC1-immunoreactivity (p = 0.005, each) in the tissue. When compared with the IR group in terms of serum levels of TRPA1 and tissue TRPA1-immunoreactivity, although there was no statistically significant difference in the IR+Ilo (p = 0.257 and p = 0.429, respectively), IR+Brl (p = 0.024 and p = 0.177, respectively), and IR+Ilo+Brl (p = 0.024 and p = 0.329, respectively) groups, serum levels of TOS and TRPC1 along with tissue TRPC1-immunoreactivity were statistically significantly reduced in the IR+Ilo (p = 0.002, p = 0.008, and p = 0.004, respectively), IR+Brl (p = 0.004, p = 0.008, and p = 0.004, respectively), and IR+Ilo+Brl groups (p = 0.002, p = 0.008, and p = 0.004, respectively).
In IR group serum TOS, TRPA1 and TRPC1 levels ,and tissue TRPA1 and TRPC1 immunoreactivity were statistically significant increase when compared to the sham group. In IR+ILO, IR+BRL and IR+ILO+BRL groups serum TRPA1 and tissue TRPA1 immunoreactivity did not change when compared to IR group. Serum TOS and TRPC1 levels, tissue TRPC1 immunoreactivty were statistically significant decreased when compared to IR group. More detailed and expanded population studies are needed to discuss our results.
在这项研究中,我们旨在探讨抗氧化剂伊洛前列素(ILO)和β3 肾上腺素能受体激动剂(BRL)对实验性缺血再灌注损伤模型中瞬时受体电位锚蛋白 1(TRPA1)和瞬时受体电位经典型 1(TRPC1)离子通道的影响,共纳入 30 只 8-10 周龄雄性 Wistar 白化大鼠。
Wistar 白化大鼠分为 5 组,假手术组(I 组)、缺血再灌注组(II 组)、伊洛前列素静脉注射组(III 组)、BRL 腹腔注射组(IV 组)和伊洛前列素静脉注射+BRL 腹腔注射组(V 组)。ILO 组给予 2ng/kg/min 伊洛前列素静脉输注,BRL 组给予 5μg/kg 单次腹腔内注射。酶联免疫吸附试验(ELISA)检测血清中总氧化状态(TOS)、TRPA1 和 TRPC1 水平,免疫组织化学染色检测股四头肌组织中 TRPA1 和 TRPC1 的免疫反应性。
与假手术组相比,缺血再灌注组血清 TOS(p=0.004)、TRPA1(p=0.002)和 TRPC1(p=0.008)水平以及组织中 TRPA1 和 TRPC1 免疫反应性(p=0.005,各)均显著升高。与缺血再灌注组相比,虽然伊洛前列素组(p=0.257 和 p=0.429)、BRL 组(p=0.024 和 p=0.177)和伊洛前列素+BRL 组(p=0.024 和 p=0.329)血清 TRPA1 和组织 TRPA1 免疫反应性无统计学差异,但伊洛前列素组(p=0.002,p=0.008,p=0.004)、BRL 组(p=0.004,p=0.008,p=0.004)和伊洛前列素+BRL 组(p=0.002,p=0.008,p=0.004)血清 TOS 和 TRPC1 以及组织 TRPC1 免疫反应性均显著降低。
与假手术组相比,缺血再灌注组血清 TOS、TRPA1 和 TRPC1 水平以及组织 TRPA1 和 TRPC1 免疫反应性均显著升高。与缺血再灌注组相比,伊洛前列素组、BRL 组和伊洛前列素+BRL 组血清 TRPA1 和组织 TRPA1 免疫反应性无明显变化。与缺血再灌注组相比,伊洛前列素组、BRL 组和伊洛前列素+BRL 组血清 TOS 和 TRPC1 水平以及组织 TRPC1 免疫反应性均显著降低。需要更多详细和广泛的人群研究来讨论我们的结果。